Development of the Crohnʼs disease digestive damage score, the Lémann score

Benjamin Pariente(Hôpital Saint-Louis), Jacques Cosnes(Sorbonne Université), Silvio Danese(Fondazione Humanitas per la Ricerca), William J. Sandborn(University of California, San Diego), M. Lewin(Centre de Recherche Saint-Antoine), Joel G. Fletcher(Mayo Clinic), Yehuda Chowers(Rambam Health Care Campus), Geert D’Haens(Imelda Hospital), Brian G. Feagan(Western University), Toshifumi Hibi∥(Keio University), Daniël W. Hommes(Leiden University Medical Center), Jan E. Irvine(University of Toronto), Michael A. Kamm(St Vincent's Hospital), Edward V. Loftus(Mayo Clinic in Arizona), Édouard Louis(Centre Hospitalier Universitaire de Liège), Pierre Michetti(University of Lausanne), Pia Munkholm(Herlev Hospital), Tom Öresland(Akershus University Hospital), Julián Panés(Hospital Clínic de Barcelona), Laurent Peyrin‐Biroulet(Centre Hospitalier Régional et Universitaire de Nancy), Walter Reinisch(Medical University of Vienna), Bruce E. Sands(Harvard University), Juergen Schöelmerich(University Hospital Frankfurt), Stefan Schreiber(Kiel University), Herbert Tilg(Christian Doppler Laboratory for Thermoelectricity), Simon Travis(John Radcliffe Hospital), Gert Van Assche(KU Leuven), Maurizio Vecchi(University of Milan), Jean-Yves Mary(Hôpital Saint-Louis), Jean‐Frédéric Colombel(Hôpital Claude Huriez), Marc Lémann(Hôpital Saint-Louis)
Inflammatory Bowel Diseases
November 28, 2010
Cited by 580Open Access
Full Text

Abstract

Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An instrument to measure cumulative structural damage to the bowel, which may predict long-term disability, is needed. The aim of this article is to outline the methods to develop an instrument that can measure cumulative bowel damage. The project is being conducted by the International Program to develop New Indexes in Crohn's disease (IPNIC) group. This instrument, called the Crohn's Disease Digestive Damage Score (the Lémann score), should take into account damage location, severity, extent, progression, and reversibility, as measured by diagnostic imaging modalities and the history of surgical resection. It should not be "diagnostic modality driven": for each lesion and location, a modality appropriate for the anatomic site (for example: computed tomography or magnetic resonance imaging enterography, and colonoscopy) will be used. A total of 24 centers from 15 countries will be involved in a cross-sectional study, which will include up to 240 patients with stratification according to disease location and duration. At least 120 additional patients will be included in the study to validate the score. The Lémann score is expected to be able to portray a patient's disease course on a double-axis graph, with time as the x-axis, bowel damage severity as the y-axis, and the slope of the line connecting data points as a measure of disease progression. This instrument could be used to assess the effect of various medical therapies on the progression of bowel damage.


Related Papers

No related papers found

Powered by citation graph analysis